- Report
- April 2024
- 115 Pages
Global
From €4088EUR$4,500USD£3,528GBP
- Report
- July 2023
- 117 Pages
Global
From €4088EUR$4,500USD£3,528GBP
- Report
- May 2022
- 51 Pages
Global
From €2226EUR$2,450USD£1,921GBP
- Report
- June 2021
- 77 Pages
Global
From €4497EUR$4,950USD£3,881GBP
- Report
- August 2023
- 202 Pages
South Africa
From €3179EUR$3,500USD£2,744GBP
From €3179EUR$3,500USD£2,744GBP
- Report
- May 2025
- 186 Pages
Global
From €4088EUR$4,500USD£3,528GBP
- Report
- April 2025
- 122 Pages
Europe
From €3634EUR$4,000USD£3,136GBP
From €3179EUR$3,500USD£2,744GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3179EUR$3,500USD£2,744GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3179EUR$3,500USD£2,744GBP
- Report
- January 2025
- 134 Pages
Europe
From €3634EUR$4,000USD£3,136GBP
- Report
- January 2025
- 140 Pages
Asia Pacific
From €3634EUR$4,000USD£3,136GBP
- Report
- January 2025
- 140 Pages
Europe
From €3634EUR$4,000USD£3,136GBP
- Report
- December 2024
- 85 Pages
Spain
From €3179EUR$3,500USD£2,744GBP
- Report
- December 2024
- 87 Pages
Spain
From €3179EUR$3,500USD£2,744GBP
- Report
- October 2024
- 82 Pages
Saudi Arabia
From €3179EUR$3,500USD£2,744GBP
- Report
- September 2024
- 82 Pages
Japan
From €3179EUR$3,500USD£2,744GBP
- Report
- September 2024
- 80 Pages
France
From €3179EUR$3,500USD£2,744GBP
- Report
- August 2024
- 80 Pages
United States
From €3179EUR$3,500USD£2,744GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more